It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.08.24316907;](https://doi.org/10.1101/2024.11.08.24316907) this version posted November 8, 2024. The copyright holder for this preprint

1

¹**Stratifying IVF population endometria using a prognosis**

²**gradient independent of endometrial timing**

- 3 3
- 4 Josefa Maria SANCHEZ-REYES, Ph.D.^{a,b,π}
- 5 Antonio PARRAGA-LEO, M.Sc.^{a,b,π}
- 6 Patricia SEBASTIAN-LEON, Ph.D.^a
- 7 Maria del Carmen VIDAL, M.D.^c
- 8 Diana MARTI-GARCIA, M.Sc.^{a,b}
- 9 Katharina SPATH, Ph.D.^d
- 10 Immaculada SANCHEZ-RIBAS, M.D., Ph.D.^e
- 11 Francisco José SANZ, Ph.D.^a
- 12 Nuria PELLICER, M.D., Ph.D. \textdegree
- 13 Jose REMOHI, M.D., Ph.D. b,c
- 14 Dagan WELLS, Ph.D. d,f </sup>
- 15 Antonio PELLICER, M.D., Ph.D.^{b,g}
- 16 Patricia DIAZ-GIMENO, Ph.D.^{a*}
-
- 18 ^a IVIRMA Global Research Alliance, IVI Foundation, Instituto de Investigación
- 19 Sanitaria La Fe, Av. Fernando Abril Martorell 106, Torre A, Planta 1^a, 46026
- 20 Valencia, Spain.

- ^b Department of Pediatrics, Obstetrics & Gynecology, University of Valencia, Av.
- 22 Blasco Ibañez 15, 46010 Valencia, Spain.
- ^c IVIRMA Global Research Alliance, IVIRMA IVI Valencia, Plaza de la Policia
- 24 Local 3, 46015 Valencia, Spain.
- ^d JUNO Genetics, Winchester house, Edmund Halley Rd. Science Park, Oxford
- 26 OX4 4GE, United Kingdom.
- ^e IVIRMA Global Research Alliance, IVIRMA IVI Barcelona, Calle Mallorca 45,
- 28 08029 Barcelona, Spain.
- ^f Nuffield Department of Women´s & Reproductive Health, University of Oxford,
- ³⁰Level 3, Women´s Centre John Radcliffe Hospital, Oxford OX3 9DU, United
- 31 Kingdom.
- 32 ^g IVIRMA Global Research Alliance, IVIRMA IVI Rome, Largo Ildebrando
- 33 Pizzetti 1, Piano Rialzato 00197 Rome, Italy.
- 34 **T** Josefa Maria SANCHEZ-REYES and Antonio PARRAGA-LEO are joint first
- 35 authors.
-
- ³⁷*Corresponding author:

³⁸**Patricia DIAZ-GIMENO**

- 39 IVIRMA Global Research Alliance, IVI Foundation, Instituto de Investigación
40 Sanitaria La Fe (IIS La Fe). Valencia. Spain. 40 Sanitaria La Fe (IIS La Fe), Valencia, Spain.
41
-
- 42 42 Edificio Biopolo – Instituto de Investigación Sanitaria la Fe
43 Avenida Fernando Abril Martorell. 106 - Torre A. Planta 1ª.
- 43 Avenida Fernando Abril Martorell, 106 Torre A, Planta 1^a, 46026 Valencia
44 Tel: +34 96 390 33 05
- 44 Tel: +34 96 390 33 05
45 email: patricia.diaz@iv
- email: patricia.diaz@ivirma.com / patricia_diaz@iislafe.es

> $\overline{3}$

Conflict of interest

- 48 The authors report no conflicts of interest.
-

Funding

51 This study was supported by the IVI Foundation (1706-FIVI-048-PD); Instituto de Salud Carlos III (ISCIII) and co-funded by the European Regional 53 Development Fund "A way to make Europe" (PI19/00537 [P.D.-G.]). Patricia Diaz-Gimeno is supported by Instituto de Salud Carlos III (ISCIII) through the Miguel Servet program (CP20/00118) co-funded by the European Union. Patricia Sebastian-Leon is funded by Instituto de Salud Carlos III (ISCIII) through the Sara Borrell postdoctoral program (CD21/00132 [P.S.-L.]) co-58 financed by the European Union. Josefa Maria Sanchez-Reyes was supported 59 by a predoctoral fellowship program of the Generalitat Valenciana (ACIF/2018/072 [J.M.S.-R.], BEFPI/2020/028 [J.M.S.-R.]). Antonio Parraga-Leo (FPU18/01777 [A.P.-L.]) and Diana Marti-Garcia (FPU19/03247 [D.M.-G.]) were 62 supported by predoctoral fellowship programs of the Spanish Ministry of 63 Science, Innovation and Universities.

Paper presentation information

 Some of the findings reported in this scientific article were presented at the $78th$ American Society for Reproductive Medicine Scientific Congress & Expo (ASRM) held in Anaheim, California, USA, October 22-26, 2022.

⁶⁹**ABSTRACT**

Background: Independent of endometrial timing, there are molecular causes of implantation failure that disrupt the endometrial transcriptome in the mid-72 secretory phase. However, the molecular mechanisms disrupting the window of implantation (WOI) remain poorly understood. The molecular heterogeneity of this endometrial disruption must be characterized to develop personalized and more accurate diagnostic tools for preventive medicine, particularly for patients 76 with a high risk of endometrial failure.

⁷⁷**Objective(s):** This study aimed to stratify and characterize the disrupted WOI 78 patterns using endometrial timing-corrected whole gene expression and artificial ⁷⁹intelligence (AI) models in *in vitro* fertilization (IVF) patients undergoing 80 hormone replacement therapy (HRT).

⁸¹**Study design:** This multicenter prospective study was conducted between 82 January 2019 and August 2022. Endometrial biopsies were collected during the 83 mid-secretory phase for whole endometrial transcriptome analysis using RNA-⁸⁴Sequencing. To identify disruptions in the WOI, the transcriptomic variation due 85 to cyclic endometrial tissue changes was removed. Out of 195 biopsies 86 sequenced, 131 were derived from patients that met the clinical criteria to be 87 classified as having a poor prognosis (\geq 3 implantation failures, n=32) or good 88 prognosis (<3 implantation failures, n=99). The 131 patients were randomly 89 allocated to training ($n=105$) and test ($n=26$) sets for biomarker signature ⁹⁰discovery and assessment of predictive performance, respectively. The 91 reproductive outcomes of the single embryo transfer immediately after biopsy 92 collection were analyzed. Differential gene expression and functional analyses 93 were performed to characterize molecular profiles. Finally, a quantitative

5

⁹⁴polymerase chain reaction (qPCR) assay was used to corroborate the 95 differential expression of six potential biomarkers.

⁹⁶**Results:** With the dichotomous clinical classification of poor or good 97 reproductive prognosis, there was no transcriptomic distinction between 98 patients with a history of implantation failures during HRT endometrial 99 preparation. Alternatively, using an AI model to stratify IVF patients based on 100 the probability of endometrial disruption revealed molecular and clinical 101 differences between profiles. Patients were stratified into four reproductive 102 prognosis-related profiles, p1 (n=24), p2 (n=14), c2 (n=32) and c1 (n=61). The ¹⁰³highest pregnancy rate (PR) was associated with c1 (91%) and the highest 104 ongoing pregnancy rate (OPR) was associated with c2 (78%), linking these ¹⁰⁵profiles to good reproductive prognoses. On the other hand, p1 had the highest ¹⁰⁶biochemical miscarriage rate (BMR; 43%) while p2 had the highest clinical ¹⁰⁷miscarriage rate (CMR; 43%). Notably, both p1 and p2 were related to lower PR 108 and OPR, supporting that these profiles were associated with poor prognoses. ¹⁰⁹Regarding the functional characterization in the poor prognosis profiles that ¹¹⁰were linked to miscarriages, p1 was associated with an excessive immune 111 response against the embryo during early pregnancy stages, while p2 was 112 initially immune-tolerant but rejected the fetus in later stages due to the lack of 113 metabolic response.

¹¹⁴**Conclusion(s):** This new AI-based prognostic stratification of IVF patients is 115 promising for the clinical management of endometrial-factor infertility in 116 precision medicine.

6

¹¹⁷**Keywords:** gene expression signature, endometrial disruption, endometrial 118 function, artificial intelligence, transcriptomic stratification, infertility, precision 119 medicine.

120**INTRODUCTION**

¹²¹Maternal endometrial status is a key factor in successful embryo implantation 122 and development in assisted reproductive technologies $(ARTs)^1$ Cyclical 123 physiological changes occur in the endometrium during the luteal phase to 124 facilitate embryo implantation. Maximum uterine receptivity occurs during the 125 window of implantation (WOI) in the mid-secretory phase. $2-5$ To ensure 126 endometrial factor success, the endometrium must synchronize with the embryo 127 during the WOI, $6-9$ and endometrial function must be undisrupted.¹⁰⁻¹² After 128 successful embryo implantation, the endometrium must support placentation 129 and provide an optimal equilibrium of embryo-maternal interactions as well as 130 adequate vascularization for fetal growth.¹³

131 Despite the development of ARTs, approximately 35% of transferred euploid 132 embryos do not implant in anatomically normal uteri at the first attempt.¹⁴ 133 Patients experiencing successive implantation failures are clinically classified as 134 having recurrent implantation failure (RIF), however, there is a lack of 135 consensus on the definition of RIF.^{14,15} The heterogeneous etiology and clinical 136 symptoms of RIF do not provide sufficient criteria to stratify patients.^{10,16} Indeed, 137 the molecular heterogeneity of RIF patients highlights opportunities to 138 characterize the molecular profiles that contribute to the interpatient variability, 139 discover new biomarkers and develop tailored treatments.

> $\overline{7}$ 7

¹⁴⁰The combined use of transcriptomics and artificial intelligence (AI) algorithms 141 has significantly advanced the understanding of endometrial-factor infertility.^{10–10} 142 $12,17-19$ This work is laying the groundwork for new applications in precision ¹⁴³medicine and ARTs, facilitating the characterization of reproductive diseases, 144 patient diagnosis and prognosis. In this context, accurate patient stratification is 145 necessary to match treatment to the right patient.^{20–22}

¹⁴⁶Leveraging the use of AI algorithms, our group recently proposed a biomarker 147 signature in luteal-phase endometrial biopsies that stratifies ART patients 148 undergoing hormone replacement therapy (HRT) into poor or good reproductive 149 prognosis, independent of endometrial timing.¹² In contrast to previous studies 150 performed in natural cycles,¹⁰ this prospective study included clinical follow-up 151 to investigate if the prognostic transcriptome-based groups were related to 152 reproductive outcomes. Despite using a 404-gene panel, dichotomous patient 153 classification into poor or good prognosis was limited by the molecular 154 complexity of implantation failure that requires the identification of more 155 subtypes. 12

¹⁵⁶Hence, the current prospective study was designed to use the whole 157 transcriptomic profile to reproduce and refine our previous classification in a 158 new cohort of patients undergoing HRT. Our new prognostic stratification 159 elucidates the molecular heterogeneity of the endometrial disruptions in the 160 mid-secretory phase, independent of endometrial timing.

¹⁶¹**MATERIALS AND METHODS**

¹⁶²**Ethics statement**

8

¹⁶³This study was approved by the Ethics Committee of the Instituto Valenciano de 164 Infertilidad (Valencia, Spain; 1706-FIVI-048-PD). Written informed consent was 165 obtained from all participants.

¹⁶⁶**Participants and clinical follow-up**

167 Participants (n=291) were recruited for a multicentric, prospective study 168 between January 2019 and August 2022 at five private fertility clinics in Spain. ¹⁶⁹Participants were scheduled for endometrial evaluation before embryo transfer 170 due to medical indications, and met the following inclusion criteria: 18–50 years 171 old, with a body mass index (BMI) of 19-30 kg/m², undergoing HRT prior to 172 single embryo transfer (SET) with a good-quality embryo (euploidy guaranteed ¹⁷³by preimplantation genetic testing or oocytes from donors <35 years old), and 174 presenting an endometrial thickness >6.5 mm with trilaminar structure in 175 proliferative phase. Exclusion criteria were male-factor infertility (in cases with 176 autologous sperm) as the only treatment indication, untreated reproductive 177 pathologies that may compromise endometrial function, severe pre-menopausal 178 symptoms, uncontrolled systemic or metabolic disorders, and co-administered 179 medication that can interfere with ARTs.

¹⁸⁰Baseline participant characteristics were obtained from internal medical records, 181 in accordance with data protection laws in Spain.

¹⁸²**Study design**

IVF patients undergoing HRT were clinically classified according to their history of implantation failures. Endometrial biopsies were collected during the mid-185 secretory phase for RNA-Sequencing (RNA-Seq) analysis. An AI probabilistic model was developed based on the transcriptome independent of endometrial

> 9 9

187 timing, avoiding biases in transcriptomic variation due to cyclical changes in the 188 endometrium (**Supplementary Material**). The AI-determined probability of a 189 poor prognosis was used to stratify the population. Finally, the clinical outcomes ¹⁹⁰and molecular functions of the stratified profiles were studied (**Figure 1**).

¹⁹¹**Endometrial biopsy collection, sequencing and data processing**

¹⁹²Endometrial biopsies were obtained from the uterine fundus, using a cannula ¹⁹³(Pipelle Cornier, CCD Laboratories, Paris, France) under sterile conditions, after 194 approximately 120 hours of progesterone treatment in the HRT cycles. ¹⁹⁵Anonymized samples were stored in RNA-later® (Sigma-Aldrich, Madrid, Spain) 196 at -80°C. RNA was extracted using the miRNeasy Mini Kit following 197 manufacturer's instructions (Qiagen, Hilden, Germany). RNA quality was 198 assessed using the NanoDrop™ One (AF-00342, ThermoFisher Scientific,
199 Valencia. Spain) and 4200 TapeStation Svstem® (Agilent. Valencia. Spain). Valencia, Spain) and 4200 TapeStation System[®] (Agilent, Valencia, Spain). 200 Only samples that met the following RNA quality criteria were included in the 201 study: 260/280 ratio ~2.0, 260/230 ratio=1.8–2.2, RNA integrity number (RIN) 202 ≥3 and RNA fragments with more than 200 nucleotides (DV200) ≥70%.

203 Samples were sequenced using the AmpliSeq for Illumina[®] Transcriptome 204 Human Gene Expression Panel²³ in a NextSeq 500/550 system. Raw data were 205 evaluated using FastQC²⁴. STAR²⁵ was employed to align high-quality data 206 using GRCh37/hg19 as a reference. Gene counts obtained using 207 featureCounts²⁶ were normalized using Voom transformation and quantile 208 normalization in limma.²⁷ Genes with low counts were filtered using EdgeR.²⁸ 209 Outliers and possible batch effects detected using principal component analysis 210 (PCA) were corrected using limma linear models.²⁷ Finally, the transcriptomic 211 variation due to endometrial luteal phase timing effects was detected using a

10

212 transcriptomic endometrial dating (TED) model established by our group,¹⁹ then 213 removed using limma as we previously described.¹² Additional details about the ²¹⁴TED model are presented in **Supplementary Material**.

²¹⁵**Clinical classification of patients**

216 Patients were initially classified based on their clinical history of implantation 217 failures. Implantation failure was considered for patients who presented a ²¹⁸negative beta chorionic gonadotropin (β-hCG) value (≤10 IU/L) 14–16 days 219 following embryo transfer, or a biochemical miscarriage (defined by a positive 220 serum β-hCG value, but absence of pregnancy within the first 10 weeks of 221 gestation).¹⁴ Patients with at least three implantation failures were initially 222 classified as having an endometrium with a poor prognosis whereas patients 223 who achieved implantation success within the first three attempts, were initially 224 classified as having an endometrium with a good prognosis. Patients with 225 insufficient attempts were excluded from further analyses ($n=62$).

²²⁶**Patient stratification based on AI algorithms**

227 A training set (80% of samples) was employed to identify a biomarker signature 228 for endometrial disruption in the mid-secretory phase, stratify patients and 229 develop an AI-based prediction model that was externally validated in an 230 independent testing set (20% of samples).

231 The training set was used for endometrial gene signature discovery, as 232 previously described.¹⁹ Briefly, genes were listed in decreasing order, based on 233 an informativity score, using CorrelationAttributeEval²⁹ in Weka.³⁰ To study the 234 predictive performance of different sets of ordered genes, five-fold cross-235 validation processes with 100 iterations were performed independently with

11

236 support vector machine $(SVM)^{31}$ k-nearest neighbors $(kNN)^{32}$ and random 237 forest (RF) algorithms³³ using RWeka.³⁴ Among all the outputs, the signature 238 with the highest accuracy and most genes was selected and used to develop a ²³⁹balanced probabilistic model (**Supplementary Material**). The probabilistic ²⁴⁰model was internally evaluated through cross-validation (5-fold, 10 times) in 100 241 different balanced models and their performance was evaluated with the test 242 set. The range of poor prognosis probabilities obtained by running the AI model 243 in all samples was used to stratify the study cohort into the following good (c) ²⁴⁴and poor (p) prognosis profiles: c1 (probability≤0.2), c2 (probability>0.2 & 245 probability<0.5), p2 (probability≥0.5 & probability<0.8), or p1 (probability≥0.8).

²⁴⁶**Molecular characterization of the different transcriptomic profiles**

²⁴⁷The differentially expressed genes (DEGs) [False Discovery Rate (FDR)<0.05] 248 between profiles were identified using limma. Next, the functional differences 249 between the profiles were revealed with gene set enrichment analyses (GSEA) 250 performed using ClusterProfiler³⁵. Biological functions were obtained from Kyoto 251 Encyclopedia of Genes and Genomes (KEGG; September 2021 version) 36 while 252 experimental annotated terms were obtained from Gene Ontology (GO; 253 December 2021 version). 37

²⁵⁴**Remeasuring the expression of selected potential biomarkers**

255 The expression of six DEGs was evaluated in 20 samples (five samples per 256 transcriptomic profile) with quantitative polymerase chain reaction (qPCR) using 257 beta-actin (*ACTB*) as a housekeeping gene. RNA was reverse transcribed into 258 cDNA using the PrimeScript Reagent Kit (Perfect Real Time, Takara, Japan) on 259 a Thermocycler T3000 (Biometra, Ireland). The qPCR was carried out using

12

260 Power-Up SYBR Green (Thermo Fisher Scientific, MA, USA) on a StepOnePlus 261 System (Applied Biosystems, CA, USA). The specific primer sequences ²⁶²(Invitrogen, Thermo Fisher Scientific, MA, USA) are presented in **Supplemental** 263 **Table 1**. Relative gene expression was calculated using the $\Delta\Delta$ Ct method³⁸ and ²⁶⁴*ACTB* as a housekeeping gene.

²⁶⁶**Statistical analysis**

²⁶⁷Rates for reproductive outcomes [i.e., pregnancy (PR), cumulative pregnancy ²⁶⁸(CPR), live birth (LBR), biochemical miscarriage (BMR) and clinical miscarriage ²⁶⁹(CMR)] were calculated as described in the **Supplementary Material**. 270 Descriptive statistics were used to ensure homogeny of the patients' baseline 271 clinical characteristics. Continuous variables were presented as an overall 272 mean \pm standard deviation, whereas discrete variables were presented as 273 counts and percentages. Statistical differences between groups were compared 274 using the Wilcoxon rank-sum test for continuous variables and the Fisher's 275 exact test for discrete variables. All statistical analyses were conducted in R 276 (version 4.0.5, 2021-03-31).³⁹ Graphical results were generated with ggplot2.⁴⁰ 277 In all cases p<0.05 was considered statistically significant.

278

²⁷⁹**RESULTS**

²⁸⁰**Transcriptomic data and clinical characterization of patients**

²⁸¹After quality control and analysis of available clinical information (see ²⁸²**Supplementary Material** for details), 131 samples and 14,674 genes qualified

13

283 for evaluation. Patients were clinically classified as having an endometrium 284 associated with a poor $(n=32)$ or good $(n=99)$ prognosis based on the number 285 of previous implantation failures. Both groups were homogeneous in terms of 286 main clinical variables (e.g., number of patients, age, body mass index, infertility 287 type and duration, endometrial dating) (**Supplemental Table 2**), ensuring that 288 there were no potential biases in endometrial-factor transcriptomic differences. 289 As expected, the number of transfers and implantation failures were significantly 290 different between groups (p-value= $2.20e-16$) due to the clinical classification 291 criteria used for this study. However, pairwise comparison revealed there were 292 no significant differences between the good prognosis groups (c1 and c2). ²⁹³Batch effects were corrected to ensure the transcriptomic differences were 294 related to endometrial disruption independent of endometrial timing (see ²⁹⁵**Supplementary Material**).

²⁹⁶**Four new prognostic stratification groups for endometrial function**

297 Participants were stratified into four profiles using a 236-gene signature and a 298 probabilistic model that predicts endometrial profiles with 77% accuracy, 67% 299 sensitivity and 80% specificity (see **Supplementary Material** for more details). ³⁰⁰The four profiles were established as poor (p) or good (c) according to the 301 probability of presenting an endometrium associated with a poor prognosis: p1 302 (n=24) and p2 (n=14), c2 (n=32) and c1 (n=61). Clinical variables were ³⁰³homogenous for all stratified profiles (**Table 1**).

³⁰⁴As expected, the number of transfers and implantation failures were significantly 305 different between the four profiles. Profiles associated with a poor prognosis

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.08.24316907;](https://doi.org/10.1101/2024.11.08.24316907) this version posted November 8, 2024. The copyright holder for this preprint

14

306 showed lower PR (29.17%) and LBR (50.00%) coupled with higher CMR ³⁰⁷(42.86%) and BMR (42.68%) compared to the good prognosis profiles (**Figure** ³⁰⁸**2A**). These differences were statistically significant (p-value≤0.05) for all 309 outcomes except CMR (**Figure 2A**). Interestingly, the p1 profile was related to a 310 higher rate of biochemical miscarriages, the p2 profile was related to clinical ³¹¹miscarriages and the c1 profile was associated with the best reproductive 312 outcomes. When groups were compared pairwise significant differences were 313 found between the p1 and c1 groups in terms of PR (p-value=0.0011), LBR (p-314 value=0.0478) and BMR (p-value=0.0018); between p2 and c1 groups in terms 315 of LBR (p-value=0.0147) and CMR (p-value=0.0478), and finally, between the ³¹⁶p1 and c2 groups in terms of PR (p-value=0.004) (**Figure 2B**). Considering all 317 embryo transfer attempts, the cumulative PR reached 38% for p1, 76% for p2, ³¹⁸81% for c2, and 93% for c1 (**Figure 2C**).

³¹⁹**Molecular characterization of the transcriptomically-defined profiles**

With respect to c1, there were 47 DEGs identified in p2, 3 DEGs in p1 and 1 DEG in c2. Only one transcript, mitogen-activated protein kinase 8 interacting 322 protein 1 pseudogene (*LOC644172* or *MAPK8IP1P2*), was shared between p1 and c1 profiles, as well as c2 and c1 profiles (**Table 2**).

³²⁴The p2 and p1 profiles showed the highest number of functional dysregulations 325 compared to c1 (54 and 38 dysregulations, respectively). The downregulated 326 functions (30/54, 55.6%) in p2 were mainly related to immune response $(n=10)$ 327 or metabolism and energy production $(n=12)$. The upregulated functions (24/54, ³²⁸44.4%) in p2 were mainly related with nervous system and sensory perception

15

 329 (n=6), gene expression and protein degradation (n=6). Compared to the c1 330 profile, the p1 profile had mainly upregulated functions (27/38, 71.1%), which 331 were related to immune responses $(n=9)$, nervous system and sensory 332 perception $(n=6)$. Notably, most of the downregulated functions (11/38, 28.9%) ³³³in p1 were related to cellular movement and ciliary processes (n=6) (**Table 2**).

³³⁴Both poor-prognosis-related profiles had a noticeable dysregulation of immune 335 responses compared to the c1 profiles. However, the p1 was characterized by 336 nine upregulated functions while the p2 was characterized by ten ³³⁷downregulated functions. The p2 profile also presented 12 downregulated ³³⁸functions related to metabolism and energy production (**Table 2**).

³³⁹There were 22 functional dysregulations between the control profiles, with the 340 c2 presenting a dysregulated profile similar to p2. Specifically, the c2 profile 341 presented a downregulation of nine functions related to immune responses and 342 an upregulation of five functions related to the nervous system and sensory 343 perception (Table 2).

³⁴⁴**Remeasuring expression of potential biomarkers of endometrial** ³⁴⁵**disruption**

346 The expression of six DEGs was validated by qPCR. Three of these DEGs were 347 identified in the p1 vs. c1 comparison [DND microRNA-mediated repression ³⁴⁸inhibitor 1 (*DND1*), synaptotagmin 10 (*SYT10*) and mitogen-activated protein ³⁴⁹kinase 8 interacting protein 1 pseudogene (*LOC644172)*] or c2 vs. c1 350 comparison (*LOC644172*). The remaining three DEGs were selected for having 351 the highest absolute fold change between p2 and c1 [CF transmembrane

16

352 conductance regulator (*CFTR*), V-set domain containing T cell activation ³⁵³inhibitor 1 (*VTCN1*) and solute carrier family 17 member 8 (*SLC17A8*)]. Except ³⁵⁴for *SLC17A8* (**Supplemental Figure 4**), all genes showed the same gene 355 expression trends in qPCR and RNA-Seq, reinforcing their role as potential 356 biomarkers of endometrial disruption.

³⁵⁷**COMMENT**

³⁵⁸**Principal findings**

³⁵⁹This study is the first to stratify endometrial function into four transcriptomic 360 profiles, independent of endometrial timing. The four transcriptomic profiles 361 corresponded with significantly different reproductive rates, showing a gradient 362 of prognoses and highlighting the complex nature of endometrial disruption in 363 the mid-secretory phase.

³⁶⁴**Results in the context of what is known**

³⁶⁵Disrupted endometrial function, independent of luteal phase endometrial timing, ³⁶⁶was associated with a heterogeneous transcriptomic behavior among IVF 367 patients undergoing HRT, as previously reported in patients undergoing natural 368 \cdot cycles.¹⁰ Our binary prediction model (good vs. poor prognosis) was based on a 369 signature of 236 genes that characterized the transcriptomic behavior with 67% 370 sensitivity. Our model's predictive performance exceeds that of Koot's binary ³⁷¹model, which was based on a larger signature of 301 genes and reached a ³⁷²58.3% sensitivity when used to compare control and RIF patients in natural 373 cycles.¹⁰ Although we improved the predictive performance, these results

17

374 showed that using a dichotomous model to identify the gene expression 375 patterns associated with good or poor prognosis did not achieve sufficient 376 power. Our last study in patients undergoing HRT showed that stratifying 377 patients using a 404-gene panel instead of clinical criteria significantly 378 enhanced the transcriptomic and clinical differences between poor and good 379 prognosis profiles.¹² However, the probabilistic model was not tested in an 380 independent test set, impeding comparison of the model's performance. Thus, 381 in this study, the whole transcriptome was used to stratify patients into four 382 profiles according to an AI-computed probability of endometrial disruption. ³⁸³Notably, the resulting gradient of prognoses distinguished two profiles that were 384 related to different types of miscarriages.

³⁸⁶**Clinical and research implications**

³⁸⁷This work characterized four new prognostic profiles that can be used to predict 388 reproductive outcomes in IVF patients with a history of implantation failures. 389 Specifically, the p1 transcriptomic profile was related to the worst prognosis, 390 characterized by the highest BMR and the lowest PR. On a molecular level, the 391 p1 was associated with an excessive immune response, suggesting that a poor 392 feto-maternal tolerance could be driving miscarriages in the early stages of 393 pregnancy.⁴¹ Moreover, the overall downregulation of ciliary processes in this 394 cohort of patients with RIF reinforces their role in uterine disorders. 42 ³⁹⁵Alternatively, the p2 profile was related to the highest CMR and a lack of 396 immune and metabolic responses. These findings suggest that implantation is 397 facilitated by an initial immune tolerance but miscarriage occurs in subsequent 398 pregnancy stages due to energetic deficiencies. This novel hypothesis about

18

³⁹⁹the relevance of the endometrial factor in clinical miscarriages requires further ⁴⁰⁰investigation. Finally, there were two good prognosis profiles characterized by 401 high PRs and LBRs. The c1 profile was related to the highest LBR and lowest 402 BMR.

403 Overall, this new taxonomy can help improve the precision of diagnosis and 404 treatment of infertile women. It lays the groundwork for a new generation of ⁴⁰⁵tools for evaluating patients with suspected endometrial-factor infertility or 406 stratifying types of miscarriages. Additionally, the molecular and functional 407 differences between the reproductive prognosis profiles set the foundation for 408 the discovery of new biomarkers and/or tailored therapeutic targets for each 409 specific transcriptomic profile.

⁴¹⁰**Strengths and limitations**

411 This study proposed a novel stratification based on four whole-transcriptome-412 based profiles with a gradient of reproductive prognosis for IVF patients 413 undergoing HRT, improving the results from the binary classification obtained in 414 our previous studies.¹² Additionally, this approach leverages AI-computed 415 probabilities which are more objective and robust than traditional approaches to 416 classify patients with endometrial-factor infertility based on the number of 417 implantation failures.

418 However, it is worth mentioning that due to the stratification into four groups and 419 the limited sample size by group, the AI model needs further optimization. 420 Further studies with larger patient cohorts are required to boost the statistical

19

421 power of the model for population inference, assess inter-cycle reproducibility, 422 and conduct rigorous prospective clinical trials prior to clinical implementation.⁴³

⁴²⁵**Conclusions**

⁴²⁶Regardless of endometrial timing, the heterogeneous endometrial function can 427 be leveraged to stratify IVF patients undergoing HRT. This study uncovers four 428 distinct prognostic groups reflecting disrupted molecular profiles related with the 429 highest BMR and CMR (p1 and p2, respectively) or less disrupted profiles 430 associated with the highest LBR (c1) and the highest PR (c2). These molecular 431 findings were linked to functional differences, highlighting overactive immune 432 responses in p1 and decreased metabolism in p2, and revealing potential ⁴³³mechanisms of actions underlying the biochemical and clinical miscarriages in 434 this cohort. Taken together, our results support that good and poor endometrial 435 prognoses have evident molecular and clinical differences. These findings 436 advance the research in personalized diagnostic and therapeutic strategies in 437 reproductive medicine, particularly for patients with endometrial-factor infertility.

⁴³⁹**Acknowledgements**

440 The authors thank the patients who participated in the study and the clinical 441 staff who contributed to their recruitment, especially Elena Labarta, Juan ⁴⁴²Antonio García Velasco, Juan Giles, Ernesto Bosch, Agustín Ballesteros, Gema ⁴⁴³Castillón, Marcos Ferrando, Graciela Kohls, Francesca Gelosi, Laura Caracena,

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.08.24316907;](https://doi.org/10.1101/2024.11.08.24316907) this version posted November 8, 2024. The copyright holder for this preprint

20

⁴⁴⁴Marga Esbert, Isabel Llorens, Cristina Gaya, Mónica Toribio, and Fernando ⁴⁴⁵Quintana. We would like to thank Ester Castillo and Lourdes Fernandez from 446 Illumina® Spain, for their technical support for sequencing. Finally, we 447 acknowledge Raquel Amigo and Cristina Cardona from the Biobank and ⁴⁴⁸Genomics Unit of the IIS La Fe, respectively, for assisting biopsy storing and 449 processing.

⁴⁵¹**REFERENCES**

- ⁴⁵²1. Strowitzki T, Germeyer A, Popovici R, Von Wolff M. The human ⁴⁵³endometrium as a fertility-determining factor. *Human Reproduction Update*. ⁴⁵⁴2006;12(5):617-630. doi:10.1093/humupd/dml033
- ⁴⁵⁵2. Harper MJK. 10 The implantation window. *Baillière's Clinical Obstetrics and* ⁴⁵⁶*Gynaecology*. 1992;6(2):351-371. doi:10.1016/S0950-3552(05)80092-6
- 457 3. Murphy CR. Uterine receptivity and the plasma membrane transformation.
458 Cell Res. 2004:14(4):259-267. doi:10.1038/si.cr.7290227 ⁴⁵⁸*Cell Res*. 2004;14(4):259-267. doi:10.1038/sj.cr.7290227
- ⁴⁵⁹4. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. *American* ⁴⁶⁰*Journal of Obstetrics and Gynecology*. 1975;122(2):262-263. ⁴⁶¹doi:10.1016/S0002-9378(16)33500-1
- 462 5. Wilcox AJ, Baird DD, Weinberg CR. Time of Implantation of the Conceptus
463 **Addler Steates and Loss of Pregnancy.** New England Journal of Medicine. ⁴⁶³and Loss of Pregnancy. *New England Journal of Medicine*. ⁴⁶⁴1999;340(23):1796-1799. doi:10.1056/nejm199906103402304
- ⁴⁶⁵6. Diaz-Gimeno P, Sebastian-Leon P, Sanchez-Reyes JM, et al. Identifying 466 and optimizing human endometrial gene expression signatures for
467 endometrial dating. Human Reproduction. 2022;37(2):284-296. ⁴⁶⁷endometrial dating. *Human Reproduction*. 2022;37(2):284-296.
- ⁴⁶⁸doi:10.1093/humrep/deab262
- 469 7. Díaz-Gimeno P, Ruiz-Alonso M, Sebastian-Leon P, et al. Window of 470 implantation transcriptomic stratification reveals different endometrial 470 implantation transcriptomic stratification reveals different endometrial
471 Subsignatures associated with live birth and biochemical pregnancy. 471 subsignatures associated with live birth and biochemical pregnancy. *Fertility*
472 and Sterility. 2017;108(4):703-710. doi:10.1016/j.fertnstert.2017.07.007 ⁴⁷²*and Sterility*. 2017;108(4):703-710. doi:10.1016/j.fertnstert.2017.07.007
- 473 8. Díaz-Gimeno P, Horcajadas JA, Martínez-Conejero JA, et al. A genomic
474 diagnostic tool for human endometrial receptivity based on the 474 diagnostic tool for human endometrial receptivity based on the
475 transcriptomic signature. Fertility and Sterility. 2011;95(1). 475 transcriptomic signature. *Fertility and Sterility*. 2011;95(1).
476 doi:10.1016/j.fertnstert.2010.04.063
- ⁴⁷⁶doi:10.1016/j.fertnstert.2010.04.063

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.08.24316907;](https://doi.org/10.1101/2024.11.08.24316907) this version posted November 8, 2024. The copyright holder for this preprint

23

- ⁵⁵⁶32. Zhang Z. Introduction to machine learning: K-nearest neighbors. *Annals of* ⁵⁵⁷*Translational Medicine*. 2016;4(11). doi:10.21037/atm.2016.03.37
- 558 33. Breiman L. Random forests. *Machine Learning*. 2001;45(1):5-32.
559 doi:10.1023/A:1010933404324 ⁵⁵⁹doi:10.1023/A:1010933404324
- 560 34. Hornik K, Buchta C, Zeileis A. Open-source machine learning: R meets
561 Weka. Comput Stat. 2009:24(2):225-232. doi:10.1007/s00180-008-0119 ⁵⁶¹Weka. *Comput Stat*. 2009;24(2):225-232. doi:10.1007/s00180-008-0119-7
- 562 35. Yu G, Wang LG, Han Y, He QY. ClusterProfiler: An R package for
563 comparing biological themes among gene clusters. *OMICS: A Jou* 563 comparing biological themes among gene clusters. *OMICS: A Journal of 564 Integrative Biology*. 2012:16(5):284-287. doi:10.1089/omi.2011.0118 ⁵⁶⁴*Integrative Biology*. 2012;16(5):284-287. doi:10.1089/omi.2011.0118
- 565 36. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes.
566 Nucleic Acids Research. 2000:28(1):27-30. doi:10.1093/nar/28.1.27 ⁵⁶⁶*Nucleic Acids Research*. 2000;28(1):27-30. doi:10.1093/nar/28.1.27
- 567 37. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: Tool for the 358
568 The unification of biology. Nature Genetics. 2000;25(1):25-29. ⁵⁶⁸unification of biology. *Nature Genetics*. 2000;25(1):25-29.
- ⁵⁶⁹doi:10.1038/75556
- 570 38. Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using
571 Real-Time Quantitative PCR and the 2–ΔΔCT Method. *Methods*.
- 571 Real-Time Quantitative PCR and the 2-ΔΔCT Method. *Methods.*
572 2001:25(4):402-408. doi:10.1006/meth.2001.1262
- ⁵⁷²2001;25(4):402-408. doi:10.1006/meth.2001.1262
- 573 39. R Core Team. *R: A Language and Environment for Statistical Computing.* R
574 **19 Foundation for Statistical Computing: 2021. https://www.R-project.org/** ⁵⁷⁴Foundation for Statistical Computing; 2021. https://www.R-project.org/
- 575 40. Wickham H. *Ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag
576 New York; 2016. https://ggplot2.tidyverse.org New York; 2016. https://ggplot2.tidyverse.org
- 577 41. Sargent IL, Wilkins T, Redman CWG. Maternal immune responses to the 578 fetus in early pregnancy and recurrent miscarriage. The Lancet. ⁵⁷⁸fetus in early pregnancy and recurrent miscarriage. *The Lancet*. ⁵⁷⁹1988;2(8620):1099-1104. doi:10.1016/S0140-6736(88)90522-3
- 580 42. Devesa-Peiro A, Sebastian-Leon P, Garcia-Garcia F, et al. Uterine disorders
581 **Frange Feralis and Antiana and Sena** functions altered in 581 affecting female fertility: what are the molecular functions altered in
582 endometrium? Fertility and Sterility. 2020;113(6):1261-1274.
- ⁵⁸²endometrium? *Fertility and Sterility*. 2020;113(6):1261-1274.
- ⁵⁸³doi:10.1016/j.fertnstert.2020.01.025
- 584 43. Diaz-Gimeno P, Sebastian-Leon P, Pellicer A. Reply of the Authors: Altered
585 endometrial receptivity: walking across the long path of precision medicine. 585 endometrial receptivity: walking across the long path of precision medicine.
586 Fertility and Sterility. 2024;122(3):551. doi:10.1016/j.fertnstert.2024.06.010 ⁵⁸⁶*Fertility and Sterility*. 2024;122(3):551. doi:10.1016/j.fertnstert.2024.06.010
- 587

589
590 **TABLES**

25

603

605

⁶⁰⁶**Table 2. Molecular regulation and functional differences between** ⁶⁰⁷**endometrial profiles.** The table shows the number of differentially expressed ⁶⁰⁸genes (DEGs) and the corresponding number of significantly up- or 609 downregulated biological functions [False Discovery Rate (FDR) < 0.05], 610 identified through a gene set enrichment analysis (GSEA), for each comparison. 611 The number of biological functions in each functional groups is indicated 612 between brackets.

613
614

27

⁶¹⁵**FIGURE CAPTIONS**

⁶¹⁶**Figure 1. Study design.** *In vitro* fertilization (IVF) patients undergoing hormone 617 replacement therapy (HRT) were classified as having good or bad endometrial 618 prognosis profiles based on their reproductive histories. Endometrial biopsies 619 were processed for whole-transcriptome RNA-Sequencing. Following RNA-620 Sequencing data normalization, the effect of endometrial luteal-phase timing ⁶²¹was corrected. Subsequently, an artificial intelligence model was developed to 622 stratify the population into four groups according to their probability of having a 623 poor prognosis. Transcriptomic evaluation and functional characterization were 624 followed by an analysis of clinical reproductive outcomes profiles are clinically 625 relevant.

⁶²⁶**Figure 2. Clinical evaluation of transcriptomic profiles. (A)** Bar plot showing 627 the significant differences obtained through pairwise comparisons of different 628 profiles. PR, Pregnancy rate; LBR, Live birth rate; CMR, Clinical miscarriage ⁶²⁹rate; BMR, Biochemical miscarriage rate. **(B)** Bar plot showing the cumulative 630 pregnancy rate from multiple embryo transfers. *p-value < 0.05 ; **p-value < 631 0.01; ***p-value < 0.001 .

⁶³³**SUPPLEMENTARY MATERIAL**

⁶³⁴**Supplemental Table 1. Specific primers employed for qPCR** ⁶³⁵**remeasurementof endometrial disruption biomarkers.**

⁶³⁶*CFTR*, CF transmembrane conductance regulator; *DND1*, MicroRNA-mediated ⁶³⁷repression inhibitor 1; FW, forward; *MAPK8IP1P2, mitogen-activated protein*

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.08.24316907;](https://doi.org/10.1101/2024.11.08.24316907) this version posted November 8, 2024. The copyright holder for this preprint

kinase 8 interacting protein 1 pseudogene 2, also known as *LOC644172*; qPCR, quantitative polymerase chain reaction*;* RV, reverse; *SLC17A8,* solute carrier family 17 member 8; *SYT10,* synaptotagmin; *VTCN1,* V-set domain 641 containing T cell activation inhibitor 1.

Supplemental Table 2. Homogeneity of the baseline characteristics in poor and good endometrial prognosis groups.

With the transcriptomic endometrial dating (TED) model, early and late 645 secretory (ESE;LSE) classes were grouped as displaced while early and late mid-secretory (EMSE;LMSE) classes were grouped as on time. BMI, body 647 mass index; N/A, not available; No., number of. $**$ p-value < 0.001 .

Supplemental Table 3. Homogeneity of the baseline characteristics in training and test sets. Baseline characteristics of training and test sets are 650 shown. With the transcriptomic endometrial dating (TED) model, early and late 651 secretory (ESE;LSE) classes were grouped as displaced while early and late mid-secretory (EMSE;LMSE) classes were grouped as on time. BMI, body 653 mass index; N/A, not available; No., number of. *p-value $<$ 0.05; ***p-value $<$ 0.001.

Supplemental Table 4. Comparison of AI model performance metrics.

The table shows the performance metrics (accuracy, sensitivity, and specificity) 657 for individual machine learning models (SVM, RF, kNN) and their combinations (SVM+kNN, SVM+RF, kNN+RF). kNN, k-Nearest neighbors; RF, Random 659 forest; SVM, Support vector machine.

Supplemental Figure 1. Principal component analysis (PCA) results. (A) PCA plot identifying two outliers (V10 and Bi16), which were excluded from

subsequent analyses. **(B)** PCA plots depicting the batch effect from the sequencing run before and after correction. **(C)** PCA plots depicting the endometrial timing effect obtained using the 73-gene TED signature before and 665 after correction. EMSE, early mid-secretory; ESE, early secretory; LMSE, late mid-secretory; LSE, late secretory; PC, principal component; TED, 667 transcriptomic endometrial dating.

Supplemental Figure 2. Exploratory analysis of RNA quality parameters. Principal component analysis (PCA) plots for the **(A)** 260/230 ratio, **(B)** 260/280 ratio, **(C)** RNA fragments with more than 200 nucleotides (DV200), and **(D)** RNA 671 integrity number (RIN). No batch effects were observed for these parameters.

Supplemental Figure 3. Selection of the poor endometrial prognosis gene signature. Graphs highlighting the maximum number of endometrial genes the **(A)** Support vector machine (SVM), **(B)** k-Nearest neighbors (kNN) and **(C)** 675 Random Forest (RF) models can process with the highest accuracy. The 676 orange dotted line represents the percentage obtained with an unbalanced 677 proportion of good and poor prognosis classes.

Supplemental Figure 4. qPCR validation of endometrial disruption biomarkers. Comparison of gene expression fold change obtained with RNA-Sequencing (RNA-Seq) and quantitative polymerase chain reaction (qPCR) assays. Six differentially expressed genes (DEGS) were selected from **(A)** p1 vs. c1, **(B)** p2 vs. c1, **(C)** c2 vs. c1 comparisons.

 $\ddot{}$

LBR

 0.00%

PR

A)

CMR

BMR

No. embryo transfers